Three new orbifloxacin multicomponent crystal forms towards pharmaceutical improvement

Página do item simplificado
dc.creatorViana, Olimpia Maria Martins Santos
dc.creatorFreitas, Jennifer Tavares Jacon
dc.creatorChecchinato, Monalisa Bitencourt da Silva
dc.creatorMartins, Felipe Terra
dc.creatorDoriguetto, Antonio Carlos
dc.date.accessioned2023-11-20T15:27:33Z
dc.date.available2023-11-20T15:27:33Z
dc.date.issued2020
dc.description.abstractOrbifloxacin (ORBI) is a third-generation synthetic fluoroquinolone used as an antimicrobial veterinary drug for the treatment of gastrointestinal and respiratory infections. Structural information about this drug is restricted to a hemihydrate containing ORBI as a zwitterion, which is the crystal form expected to be present in veterinary solid oral formations. Since the major problem with the ORBI hemihydrate form is its poor solubility and structure conservation upon dehydration, leading to uncontrollable water contents in the active pharmaceutical ingredient (API), we present here for the first time the crystal structures of three ORBI multicomponent crystal forms including two salt solvates and one cocrystal salt solvate: a hydrochloride salt monohydrate (1), a nitrate salt monohydrate (2) and a phosphoric acid hemi-cocrystal of the dihydrogen phosphate salt monohydrate (3). The latter form presents a very interesting multicomponent crystal feature having phosphate species either as a counter-ion or a neutral coformer. Pure crystalline samples of 1–3 were obtained and characterised by powder X-ray diffraction, infrared spectroscopy, thermogravimetry and differential thermal analyses. We have provided here a full analytical dataset for three new multicomponent solid forms of orbifloxacin, which may improve drug solubility and mitigate the possible drawback of inconsistent water load inherent to its hydrated free-base form.
dc.identifier.citationSANTOS, Olimpia Maria Martins et al. Three new orbifloxacin multicomponent crystal forms towards pharmaceutical improvement. Journal of Molecular Structure, Amsterdam, v. 1217, e128371, 2020. DOI: 10.1016/j.molstruc.2020.128371. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0022286020306967?via%3Dihub. Acesso em: 14 nov. 2023.
dc.identifier.doi10.1016/j.molstruc.2020.128371
dc.identifier.issn0022-2860
dc.identifier.issne- 1872-8014
dc.identifier.urihttps://www.sciencedirect.com/science/article/abs/pii/S0022286020306967?via%3Dihub
dc.language.isoeng
dc.publisher.countryHolanda
dc.publisher.departmentInstituto de Química - IQ (RMG)
dc.rightsAcesso Restrito
dc.subjectOrbifloxacin
dc.subjectMulticomponent solid forms
dc.subjectStructural determination
dc.subjectCrystal
dc.subjectPharmaceutical compound
dc.titleThree new orbifloxacin multicomponent crystal forms towards pharmaceutical improvement
dc.typeArtigo

Arquivos

Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

IQ - Artigos publicados em periódicos